A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
PHASE3CompletedINTERVENTIONAL
Enrollment
593
Participants
Timeline
Start Date
December 31, 1998
Study Completion Date
December 31, 2000
Conditions
Alzheimer DiseaseVascular Dementia
Interventions
DRUG
galantamine hydrobromide
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00261573 - A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia | Biotech Hunter | Biotech Hunter